SELECTIVE NEUROKININ ANTAGONISTS

摘要

Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar1 and Ar2 are optionally substituted heteroaryl or optionally substituted phenyl; X1 is -O-, -S-, -SO-, -SO2-, - NR12-, -NCOR12- or -NR12SO2R15; (a) is selected from the group consisting of (b), (c), (d) and (e); X2 is -O-, -S- or -NR5-; Y is =O, =S or =NR11; Y1 is H, C1-C6 alkyl, -NR17R13, -SCH3, R19-aryl(CH2)n6-, R19-heteroaryl-(CH2)n6-, - (CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R15; R1, R2, R3 and R7 are H, alkyl, cycloalkyl, -CHF2, -CH2F or -CF3; or R1 and R2, together with the carbon to which they are attached, form an alkylene ring; or R1 and R2 together are =O; R6 is R7 or -OH; and the remaining variables are as defined in the specification, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds. Al so disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and i n combination with an effective amount of a selective serotonin reuptake inhibitor.